Real world evidence of administration of biologic agents in patients with severe asthma: an analysis of the Respiratory Department of University Hospital of Patras

Résumé fourni par la source

Background: Real-world data on currently used biologic agents in patients with severe asthma are lacking. Methods: We recorded between 16/5/2020 and 31/12/2024 patients with severe asthma treated with biologic agent. Results: We identified 80 patients with severe asthma treated with biologic agents. Median age (95% CI) at the time of diagnosis was 67 (61 to 70) years. Most patients were female (52.0%, n=65) and never smokers (51.3%, n= 41). Median value of ACT (95% CI) was 15 (15 to 16) at the time of diagnosis. Mean FEV1% predicted ±SD at the baseline was 68.9 ± 22.0. Median value of blood eosinophils (95% CI) was 365 (252 to 448) K/μL in the overall population. One third (36.3%) of patients were hospitalized due to severe asthma exacerbation in the previous year. Longitudinal use of oral corticosteroids was recorded in 11.3% of included patients. Three patients (3.8%) were treated with omalizumab, 23 patients (28.8%) with mepolizumab, 33 patients (41.2%) with benralizumab and 21 patients (26.2%) with tezepelumab. Median value of ACT (95% CI) post biologic treatment at 6-month follow-up was 20 (20 to 21). Mean FEV1% predicted ±SD at 6-month follow-up was 77.6 ± 25.2. Median value of blood eosinophils (95% CI) 6 months after initiation of biologic treatment was 100 (40 to 121) K/μL. Elimination of hospitalizations due to asthma flares was recorded in 97.5% of patients. With regards to longitudinal use of oral corticosteroids, we noticed that 96.2% of patients achieved discontinuation. Conclusion: Administration of current biologic agents in patients with severe asthma is both effective and safe.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.